WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: A case report

Pediatric Hematology and Oncology

Volumn 26, Issue 1, 2009, Pages 74-83

  Ohta, Hideaki ^a   Hashii, Yoshiko ^a   Yoneda, Akihiro ^a   Takizawa, Sachiko ^a   Kusuki, Shigenori ^a   Tokimasa, Sadao ^a   Fukuzawa, Masahiro ^a   Tsuboi, Akihiro ^a   Murao, Ayako ^a   Oka, Yoshihiro ^a   Oji, Yusuke ^a   Aozasa, Katsuyuki ^a   Nakatsuka, Shin Ichi ^b   Sugiyama, Haruo ^a   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

Author keywords

Childhood; Rhabdomyosarcoma; WT1 peptide immunotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ARTICLE; BONE DISEASE; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NEPHROBLASTOMA; PHENOTYPE; PRESCHOOL CHILD; RHABDOMYOSARCOMA;

BONE DISEASES; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; PEPTIDE FRAGMENTS; RHABDOMYOSARCOMA, ALVEOLAR; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; WT1 PROTEINS;

EID: 61649105779     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010802435500     Document Type: Article

References (19)

1. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene?. Int Rev Cytol. 1998;181:151-212.
2. Ojiy , Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194-204.
3. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-2884.
4. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;88:2267-2278.
5. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res. 2002;8:1167-1171.
6. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814.
7. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78:56-61.
8. Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases. Microbiol Immunol. 2004;48:175-184.
9. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-13890.
10. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical tial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108:963-971.
11. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother. 2002;51:614-620.
12. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
13. Kawakami M, Oka Y, Tsuboi A, et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol. 2007;85:426-429.
14. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
15. Sotensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHP and PAX7-FKHR gene fusions are prognostic indicators in alveolat rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679.
16. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21:78-84.
17. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164:1873-1880.
18. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000;20:195-202.
19. Oka Y, Tsuboi A, Elisseeva OA, et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific World Journal. 2007;7:649-665.